What is the debate topic for the following sentences?

1. Testing new drugs is a very expensive process , in 2000 the average cost was estimated at around 86 million for the large scale phase III tests however this is contested and it could be much higher it represents 40 % of pharmaceutical companies R&D expenditures , which since a recent estimated the development cost of a drug can be up to $ 5.8 billion -LRB- due to including failures -RRB- the cost of trials would in some cases then be $ 2billion , which is currently funded by pharmaceutical companies .
2. They fund these tests because it is either impossible , very difficult or very risky to access large markets before testing has been completed -LRB- e.g. in the USA companies are only allowed to sell new drugs off-study , i.e. during trials , at cost -RRB- If you allow all terminally ill patients access to experimental drugs , you reduce the incentive for companies to continue testing their products : they will have access to a large market prior to the completion of testing , and will therefore have no incentive to complete trials , which are expensive and risk finding the product ineffective .
3. 1 DiMasi , Joseph A. et al. , The price of innovation : new estimates of drug development costs , , Vol .22 , 2003 , pp.151-185 , p. 162 2 Roy , Avik S. A. , Stifling New Cures : The True Cost of Lengthy Clinical Drug Trials , , No. 5 , April 2012 , 3 Schklenk , Udo , and Lowry , Christopher , Terminal illness and access to Phase 1 experimental agents , surgeries and devices : reviewing the ethical arguments , , Vol .89 , 2009 , pp.7-22 ,
This House would grant those diagnosed with terminal illnesses the right to access treatments that have not completed clinical testing
Vad är debattens ämne för följande meningar? 1. Testning av nya läkemedel är en mycket dyr process , år 2000 beräknades den genomsnittliga kostnaden till omkring 86 miljoner för den storskaliga fas III tester men detta är ifrågasatt och det kan vara mycket högre det representerar 40 % av läkemedelsföretagen FoU utgifter , som sedan en nyligen uppskattade utvecklingskostnaden för en drog kan vara upp till $ 5,8 miljarder - LRB-på grund av att inkludera misslyckanden - RRB- kostnaden för prövningar skulle i vissa fall då vara $ 2 miljarder , som för närvarande finansieras av läkemedelsföretag . 2. De finansierar dessa tester eftersom det antingen är omöjligt, mycket svårt eller mycket riskabelt att komma in på stora marknader innan testningen har slutförts -LRB- t.ex. I USA får företag endast sälja nya läkemedel utanför studierna, dvs. under försök, till priset -RRB- Om du tillåter alla dödssjuka patienter tillgång till experimentella läkemedel, du minskar incitamentet för företag att fortsätta testa sina produkter: de kommer att ha tillgång till en stor marknad innan slutförandet av tester, och kommer därför inte att ha något incitament att slutföra prövningar, som är dyra och riskerar att hitta produkten ineffektiv. 3. 1 DiMasi, Joseph A. et al. , Priset på innovation : nya uppskattningar av kostnaderna för läkemedelsutveckling , , Vol .22 , 2003 , s.151-185 , s. 162 2 Roy , Avik S. A , Stifling Nya botemedel : Den verkliga kostnaden för långa kliniska läkemedelstester , , Nr. 5 , April 2012 , 3 Schklenk , Udo , och Lowry , Christopher , Terminal sjukdom och tillgång till fas 1 experimentella agenter , operationer och enheter : granska de etiska argument , , Vol .89 , 2009 , s.7-22 ,
What is the subject of the debate for the following sentences? 1. Testing of new drugs is a very expensive process, in 2000, the average cost was estimated at around 86 million for the large-scale phase III tests but this is contested and it may be much higher it represents 40% of pharmaceutical companies R & D spending, which since a recently estimated development cost of a drug could be up to $5.8 billion - LRB- due to including failures - the RRB cost of trials would in some cases then be $2 billion, which is currently funded by pharmaceutical companies. 2. They finance these tests because it is either impossible, very difficult or very risky to enter large markets before testing has been completed - LRB- e.g. In the United States, companies are only allowed to sell new drugs outside of their studies, i.e. during trials, at the price -RRB- If you allow all terminally ill patients access to experimental drugs, you reduce the incentive for companies to continue testing their products: they will have access to a large market before completing tests, and will therefore have no incentive to complete trials, which are expensive and risk finding the product ineffective. 3. 1 DiMasi, Joseph A. et al. , The price of innovation : new estimates of the costs of drug development , , Vol .22 , 2003, pp.151-185 , p. 162 2 Roy , Avik S. A , Stifling New remedies : The real cost of long clinical drug tests , , No. 5, April 2012 , 3 Schklenk , Udo , and Lowry , Christopher , Terminal disease and access to phase 1 experimental agents , operations and units : review the ethical arguments , , Vol .89 , 2009 , pp.7-22 ,
Parlamentet skulle ge dem som diagnostiserats med terminala sjukdomar rätt att få tillgång till behandlingar som inte har genomgått kliniska tester.
Parliament would give those diagnosed with terminal diseases the right to access treatments that have not undergone clinical tests.